WorldCat Linked Data Explorer

http://worldcat.org/entity/work/id/119933552

Best practices in biotechnology business development valuation, licensing, cash flow, pharmacoeconomics, market selection, communication, and intellectual property

Open All Close All

http://schema.org/description

  • "The mainstream of today's biotechnology companies are small- and medium-sized companies. Only 10 per cent of European biotechnology companies have more than 50 employees, and over half employ less than 20 people. Nearly 70 per cent of Swedish biotechnology companies employ fewer than 10 people.2 The fundamental origin of most biotechnology companies come from the academia in the form of spin-off companies, via Technology-Transfer Offices. Another source of biotechnology companies is science parks and business incubators, where the goal of incubators is to decrease the chance that a start-up will fail, and shorten the time and reduce the cost of establishing and growing its business. The present work by Yali Friedman is set out to bring together a set of best practices to be used as a framework upon which to understand critical issues in biotechnology business development. Eleven chapters, covering vital aspects of valuation, licensing, cash flow, pharmacoeconomics, market selection, communication and intellectual property (IP) rights, seek to nurture the hungry minds of scientists, business developers and bioentrepreneurs alike."

http://schema.org/name

  • "Best practices in biotechnology business development : valuation, licensing, cash flow, pharmacoeconomics, market selection, communication, and intellectual property"
  • "Best practices in biotechnology business development : valuation, licensing, cash flow, pharmacoeconomics, market selection, communication, intellectual property"
  • "Best practices in biotechnology business development"
  • "Best practices in biotechnology business development valuation, licensing, cash flow, pharmacoeconomics, market selection, communication, and intellectual property"@en